Marina Bozilenko - Oct 10, 2023 Form 4 Insider Report for ACELRX PHARMACEUTICALS INC (ACRX)

Role
Director
Signature
/s/ Martha Adler, Attorney-In-Fact
Stock symbol
ACRX
Transactions as of
Oct 10, 2023
Transactions value $
$0
Form type
4
Date filed
12/13/2023, 04:25 PM
Previous filing
Jul 15, 2022
Next filing
Jun 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRX Common Stock Award $0 +581 +28.69% $0.00 2.61K Oct 10, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRX Stock Option (Right to Buy) Award $0 +3.49K $0.00 3.49K Oct 10, 2023 Common Stock 3.49K $0.68 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.
F3 Effective on October 25, 2022, the issuer effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F4 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.